Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
The clinical study will include 2 parts. Part 1 will estimate the MTD in dose escalation cohorts in patients with advanced solid tumors for whom no standard therapy is available in order to establish the RP2D. Part 2 will include patients with previously treated metastatic triple negative breast cancer (TNBC).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy or for whom no standard therapy is available
Performance Status of 0 or 1
Adequate bone marrow, kidney, and liver function
Part 2 includes advanced triple negative breast cancer patients.
You may not be if
Brain metastases requiring steroids
Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of study treatment start
Active and clinically significant bacterial, fungal or viral infection
